Does the media favor NRIX or ACRS?

In the previous week, Aclaris Therapeutics had 2 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 4 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.12 beat Aclaris Therapeutics' score of -0.15 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACRS or SLS?

In the previous week, Aclaris Therapeutics had 5 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 1 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.25 beat Aclaris Therapeutics' score of -0.15 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral SELLAS Life Sciences Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACRS or ADMA?

In the previous week, Aclaris Therapeutics had 4 more articles in the media than ADMA Biologics. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 2 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.67 beat Aclaris Therapeutics' score of -0.15 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VRDN or ACRS?

In the previous week, Aclaris Therapeutics had 2 more articles in the media than Viridian Therapeutics. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.52 beat Aclaris Therapeutics' score of -0.15 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VERA or ACRS?

In the previous week, Vera Therapeutics had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 7 mentions for Vera Therapeutics and 6 mentions for Aclaris Therapeutics. Vera Therapeutics' average media sentiment score of 0.16 beat Aclaris Therapeutics' score of -0.15 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Aclaris Therapeutics (ACRS) Competitors

$3.83 +0.04 (+1.06%)

Closing price 04:00 PM Eastern

Extended Trading

$3.80 -0.04 (-0.91%)

As of 04:38 PM Eastern

Compare

ACRS vs. NRIX, SLS, ADMA, VRDN, and VERA

Should you buy Aclaris Therapeutics stock or one of its competitors? Aclaris Therapeutics's main competitors and comparable companies include Nurix Therapeutics (NRIX), SELLAS Life Sciences Group (SLS), ADMA Biologics (ADMA), Viridian Therapeutics (VRDN), and Vera Therapeutics (VERA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aclaris Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Aclaris Therapeutics (NASDAQ:ACRS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, Aclaris Therapeutics had 2 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 4 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.12 beat Aclaris Therapeutics' score of -0.15 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.3% of Aclaris Therapeutics shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aclaris Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	27.45	-$264.46M	-$3.45	N/A
Aclaris Therapeutics	$8.22M	64.48	-$64.92M	-$0.58	N/A

Aclaris Therapeutics has a net margin of -921.50% compared to Nurix Therapeutics' net margin of -928.44%. Aclaris Therapeutics' return on equity of -61.65% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

Nurix Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Nurix Therapeutics currently has a consensus price target of $34.21, indicating a potential upside of 54.05%. Aclaris Therapeutics has a consensus price target of $11.33, indicating a potential upside of 199.03%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Summary

Aclaris Therapeutics beats Nurix Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Aclaris Therapeutics compare to SELLAS Life Sciences Group?

Aclaris Therapeutics (NASDAQ:ACRS) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

SELLAS Life Sciences Group has lower revenue, but higher earnings than Aclaris Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$8.22M	64.48	-$64.92M	-$0.58	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A

SELLAS Life Sciences Group has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. SELLAS Life Sciences Group's return on equity of -35.91% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aclaris Therapeutics presently has a consensus target price of $11.33, indicating a potential upside of 199.03%. SELLAS Life Sciences Group has a consensus target price of $10.00, indicating a potential downside of 11.19%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aclaris Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Aclaris Therapeutics had 5 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 1 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.25 beat Aclaris Therapeutics' score of -0.15 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
SELLAS Life Sciences Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aclaris Therapeutics has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.56, indicating that its share price is 156% more volatile than the broader market.

Summary

Aclaris Therapeutics beats SELLAS Life Sciences Group on 9 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to ADMA Biologics?

Aclaris Therapeutics (NASDAQ:ACRS) and ADMA Biologics (NASDAQ:ADMA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

Aclaris Therapeutics presently has a consensus target price of $11.33, suggesting a potential upside of 199.03%. ADMA Biologics has a consensus target price of $18.67, suggesting a potential upside of 80.70%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Aclaris Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Aclaris Therapeutics had 4 more articles in the media than ADMA Biologics. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 2 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.67 beat Aclaris Therapeutics' score of -0.15 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ADMA Biologics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$8.22M	64.48	-$64.92M	-$0.58	N/A
ADMA Biologics	$510.17M	4.54	$146.93M	$0.70	14.76

Aclaris Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

ADMA Biologics has a net margin of 32.98% compared to Aclaris Therapeutics' net margin of -921.50%. ADMA Biologics' return on equity of 40.17% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
ADMA Biologics	32.98%	40.17%	26.97%

Summary

Aclaris Therapeutics beats ADMA Biologics on 9 of the 17 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Viridian Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Aclaris Therapeutics (NASDAQ:ACRS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Aclaris Therapeutics had 2 more articles in the media than Viridian Therapeutics. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.52 beat Aclaris Therapeutics' score of -0.15 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.3% of Aclaris Therapeutics shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aclaris Therapeutics has lower revenue, but higher earnings than Viridian Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	29.33	-$342.60M	-$3.37	N/A
Aclaris Therapeutics	$8.22M	64.48	-$64.92M	-$0.58	N/A

Viridian Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Viridian Therapeutics presently has a consensus target price of $38.69, suggesting a potential upside of 110.97%. Aclaris Therapeutics has a consensus target price of $11.33, suggesting a potential upside of 199.03%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Viridian Therapeutics has a net margin of -505.86% compared to Aclaris Therapeutics' net margin of -921.50%. Aclaris Therapeutics' return on equity of -61.65% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

Summary

Aclaris Therapeutics beats Viridian Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Aclaris Therapeutics (NASDAQ:ACRS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Aclaris Therapeutics has higher revenue and earnings than Vera Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A
Aclaris Therapeutics	$8.22M	64.48	-$64.92M	-$0.58	N/A

Vera Therapeutics presently has a consensus target price of $80.15, indicating a potential upside of 169.61%. Aclaris Therapeutics has a consensus target price of $11.33, indicating a potential upside of 199.03%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vera Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

In the previous week, Vera Therapeutics had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 7 mentions for Vera Therapeutics and 6 mentions for Aclaris Therapeutics. Vera Therapeutics' average media sentiment score of 0.16 beat Aclaris Therapeutics' score of -0.15 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vera Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Aclaris Therapeutics' return on equity of -61.65% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-84.13%	-66.79%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

Summary

Vera Therapeutics and Aclaris Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Aclaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRS vs. The Competition

Export

Metric	Aclaris Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$535.53M	$3.89B	$7.19B	$13.28B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-6.60	13.54	274.47	26.16
Price / Sales	65.16	1,185.17	585.00	81.25
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	4.51	17.18	11.21	6.34
Net Income	-$64.92M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-12.76%	-1.17%	-0.83%	-1.36%
1 Month Performance	-31.12%	-9.68%	-5.42%	-4.29%
1 Year Performance	96.41%	10.04%	4.36%	-0.33%

Aclaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRS Aclaris Therapeutics	1.8954 of 5 stars	$3.83 +1.1%	$11.33 +195.9%	+99.5%	$535.53M	$8.22M	N/A	73	High Trading Volume
NRIX Nurix Therapeutics	2.2078 of 5 stars	$22.88 -0.5%	$34.21 +49.5%	+122.5%	$2.37B	$83.98M	N/A	357
SLS SELLAS Life Sciences Group	0.2179 of 5 stars	$11.63 -0.9%	$10.00 -14.0%	+483.4%	$2.35B	N/A	N/A	13
ADMA ADMA Biologics	3.2887 of 5 stars	$10.11 +4.0%	$18.67 +84.6%	-29.3%	$2.26B	$512.28M	14.44	647
VRDN Viridian Therapeutics	2.5686 of 5 stars	$19.00 -2.1%	$38.69 +103.6%	-14.1%	$2.15B	$70.85M	N/A	252

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRS) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. NRIX, SLS, ADMA, VRDN, and VERA

How does Aclaris Therapeutics compare to Nurix Therapeutics?

Summary

How does Aclaris Therapeutics compare to SELLAS Life Sciences Group?

Summary

How does Aclaris Therapeutics compare to ADMA Biologics?

Summary

How does Aclaris Therapeutics compare to Viridian Therapeutics?

Summary

How does Aclaris Therapeutics compare to Vera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. NRIX, SLS, ADMA, VRDN, and VERA

How does Aclaris Therapeutics compare to Nurix Therapeutics?

Does the media favor NRIX or ACRS?

Do institutionals and insiders have more ownership in NRIX or ACRS?

Which has stronger valuation and earnings, NRIX or ACRS?

Is NRIX or ACRS more profitable?

Which has more volatility and risk, NRIX or ACRS?

Do analysts prefer NRIX or ACRS?

Summary

How does Aclaris Therapeutics compare to SELLAS Life Sciences Group?

Which has better valuation & earnings, ACRS or SLS?

Is ACRS or SLS more profitable?

Do institutionals and insiders believe in ACRS or SLS?

Do analysts prefer ACRS or SLS?

Does the media prefer ACRS or SLS?

Which has more risk and volatility, ACRS or SLS?

Summary

How does Aclaris Therapeutics compare to ADMA Biologics?

Do analysts prefer ACRS or ADMA?

Does the media prefer ACRS or ADMA?

Do insiders and institutionals have more ownership in ACRS or ADMA?

Which has stronger earnings & valuation, ACRS or ADMA?

Which has more volatility & risk, ACRS or ADMA?

Is ACRS or ADMA more profitable?

Summary

How does Aclaris Therapeutics compare to Viridian Therapeutics?

Does the media prefer VRDN or ACRS?

Do institutionals and insiders have more ownership in VRDN or ACRS?

Which has preferable earnings and valuation, VRDN or ACRS?

Which has more volatility & risk, VRDN or ACRS?

Do analysts recommend VRDN or ACRS?

Is VRDN or ACRS more profitable?

Summary

How does Aclaris Therapeutics compare to Vera Therapeutics?

Which has better earnings & valuation, VERA or ACRS?

Do analysts rate VERA or ACRS?

Do institutionals and insiders hold more shares of VERA or ACRS?

Which has more risk and volatility, VERA or ACRS?

Does the media favor VERA or ACRS?

Is VERA or ACRS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools